Literature DB >> 27545901

Pandemic Risk Assessment Model (PRAM): a mathematical modeling approach to pandemic influenza planning.

D C Dover1, E M Kirwin1, N Hernandez-Ceron2, K A Nelson3.   

Abstract

The Pandemic Risk Assessment Model (PRAM) is a mathematical model developed to analyse two pandemic influenza control measures available to public health: antiviral treatment and immunization. PRAM is parameterized using surveillance data from Alberta, Canada during pandemic H1N1. Age structure and risk level are incorporated in the compartmental, deterministic model through a contact matrix. The model characterizes pandemic influenza scenarios by transmissibility and severity properties. Simulating a worst-case scenario similar to the 1918 pandemic with immediate stockpile release, antiviral demand is 20·3% of the population. With concurrent, effective and timely immunization strategies, antiviral demand would be significantly less. PRAM will be useful in informing policy decisions such as the size of the Alberta antiviral stockpile and can contribute to other pandemic influenza planning activities and scenario analyses.

Entities:  

Keywords:  Influenza; mathematical modelling; pandemic; public health

Year:  2016        PMID: 27545901      PMCID: PMC9150189          DOI: 10.1017/S0950268816001850

Source DB:  PubMed          Journal:  Epidemiol Infect        ISSN: 0950-2688            Impact factor:   4.434


  67 in total

1.  Emergence of drug-resistant influenza virus: population dynamical considerations.

Authors:  Roland R Regoes; Sebastian Bonhoeffer
Journal:  Science       Date:  2006-04-21       Impact factor: 47.728

2.  Optimal control for pandemic influenza: the role of limited antiviral treatment and isolation.

Authors:  Sunmi Lee; Gerardo Chowell; Carlos Castillo-Chávez
Journal:  J Theor Biol       Date:  2010-04-09       Impact factor: 2.691

3.  Influenza pandemic preparedness in France: modelling the impact of interventions.

Authors:  Aoife Doyle; Isabelle Bonmarin; Daniel Lévy-Bruhl; Yann Le Strat; Jean-Claude Desenclos
Journal:  J Epidemiol Community Health       Date:  2006-05       Impact factor: 3.710

4.  Seasonal influenza in the United States, France, and Australia: transmission and prospects for control.

Authors:  G Chowell; M A Miller; C Viboud
Journal:  Epidemiol Infect       Date:  2007-07-18       Impact factor: 2.451

5.  Strategies for the use of oseltamivir and zanamivir during pandemic outbreaks.

Authors:  Elsa Hansen; Troy Day; Julien Arino; Jianhong Wu; Seyed M Moghadas
Journal:  Can J Infect Dis Med Microbiol       Date:  2010       Impact factor: 2.471

6.  Modeling control strategies for concurrent epidemics of seasonal and pandemic H1N1 influenza.

Authors:  Olivia Prosper; Omar Saucedo; Doria Thompson; Griselle Torres-Garcia; Xiaohong Wang; Carlos Castillo-Chavez
Journal:  Math Biosci Eng       Date:  2011-01       Impact factor: 2.080

7.  Using a Dynamic Model to Consider Optimal Antiviral Stockpile Size in the Face of Pandemic Influenza Uncertainty.

Authors:  Amy L Greer; Dena Schanzer
Journal:  PLoS One       Date:  2013-06-21       Impact factor: 3.240

8.  Pandemic influenza and healthcare demand in the Netherlands: scenario analysis.

Authors:  Marianne L L van Genugten; Marie-Louise A Heijnen; Johannes C Jager
Journal:  Emerg Infect Dis       Date:  2003-05       Impact factor: 6.883

9.  Antiviral prophylaxis and isolation for the control of pandemic influenza.

Authors:  Qingxia Zhang; Dingcheng Wang
Journal:  Int J Environ Res Public Health       Date:  2014-07-31       Impact factor: 3.390

10.  The natural viral load profile of patients with pandemic 2009 influenza A(H1N1) and the effect of oseltamivir treatment.

Authors:  Iris W Li; Ivan F Hung; Kelvin K To; Kwok-Hung Chan; Samson S Y Wong; Jasper F Chan; Vincent C Cheng; Owen T Tsang; Sik-To Lai; Yu-Lung Lau; Kwok-Yung Yuen
Journal:  Chest       Date:  2010-01-08       Impact factor: 9.410

View more
  2 in total

1.  Epidemiological and economic impact of pandemic influenza in Chicago: Priorities for vaccine interventions.

Authors:  Nargesalsadat Dorratoltaj; Achla Marathe; Bryan L Lewis; Samarth Swarup; Stephen G Eubank; Kaja M Abbas
Journal:  PLoS Comput Biol       Date:  2017-06-01       Impact factor: 4.475

2.  A Net Benefit Approach for the Optimal Allocation of a COVID-19 Vaccine.

Authors:  Erin Kirwin; Ellen Rafferty; Kate Harback; Jeff Round; Christopher McCabe
Journal:  Pharmacoeconomics       Date:  2021-06-17       Impact factor: 4.981

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.